Clayton Eiswirth, MD
Pulmonary Disease · Metairie, LANPI 1639307861
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (56.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Boehringer Ingelheim at 50.0% of the total. Reporting peaked in 2019 at $3,581 and has fallen 97.7% since, to $81 in 2025.
Across 392 payments — averaging $28.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$6K
- GSK$2K
- AstraZeneca$1K
- Sunovion Pharmaceuticals Inc.$419
- Johnson & Johnson$310
- Regeneron Healthcare Solutions, Inc.$287
- plus $2K from 22 others
What the payments were for
- Consulting fees$1171%
- Speaking & faculty fees$4,87543%
- Food & beverage$6,36656%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 50 | $5,684 |
| GSK | 122 | $1,646 |
| AstraZeneca | 71 | $1,298 |
| Sunovion Pharmaceuticals Inc. | 31 | $419 |
| Johnson & Johnson(2 entities) | 10 | $310 |
| Regeneron Healthcare Solutions, Inc. | 15 | $287 |
| Sanofi | 14 | $279 |
| Actelion Pharmaceuticals US, Inc. | 10 | $247 |
| Mylan Specialty L.p. | 11 | $199 |
| United Therapeutics Corporation | 7 | $149 |
| Bayer | 8 | $148 |
| Grifols USA, LLC | 5 | $96 |
| Electromed, Inc. | 9 | $82 |
| Genentech USA, Inc. | 4 | $75 |
| Insmed, Inc. | 4 | $65 |
| Philips North America LLC | 4 | $63 |
| E.r. Squibb & Sons, L.L.C. | 4 | $50 |
| Baxter Healthcare | 2 | $48 |
| Inogen, Inc. | 2 | $39 |
| Inari Medical, Inc. | 1 | $24 |
| Gilead | 1 | $24 |
| Merck | 1 | $22 |
| Amgen | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $18 |
| Novartis | 1 | $16 |
| Medtronic | 1 | $15 |
| Circassia Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$125
How this compares
$11,358 in reported general payments places this provider in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 458 | $486,426 |
| OfevNintedanib Esylate | 21 | $386,635 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 16 | $242,611 |
| AdempasRiociguat | 13 | $182,682 |
| NucalaMepolizumab | 20 | $147,941 |
| Breo ElliptaFluticasone/Vilanterol | 119 | $79,169 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 67 | $54,544 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 49 | $37,822 |
| EliquisApixaban | 41 | $27,188 |
| Spiriva RespimatTiotropium Bromide | 40 | $26,219 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 39 | $23,728 |
| SymbicortBudesonide/Formoterol Fumarate | 63 | $19,810 |
| Arnuity ElliptaFluticasone Furoate | 42 | $14,884 |
| XareltoRivaroxaban | 26 | $14,455 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 423 | $10,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $1,646 | $752,149678 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat | $5,684 | $450,675110 claims |
| Insmed, Inc.Arikayce | $65 | $242,61116 claims |
| BayerAdempas | $148 | $182,68213 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,298 | $74,354130 claims |
| Johnson & JohnsonXarelto | $310 | $14,45526 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Metairie
- Sneha SamantMetairie$13K
- Sam SeylerMetairie$13K
- Thomas NuttliMetairie$9K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
- Warren BotnickNatchitoches$213K
- Nicole LapinelNew Orleans$140K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.